Research graph
References from Cost comparison of pdVWF/FVIII prophylaxis and on-demand therapy in type 3 von Willebrand disease in the United States. Local targets link to admitted publications; unresolved targets remain external evidence.
Von Willebrand’s Disease
10.1056/nejmra1601561 · 2016 · External reference
Prophylactic management of patients with von Willebrand disease
10.1177/20406207211064064 · 2021 · External reference
Sexism in the management of bleeding disorders
10.1002/rth2.12468 · 2021 · External reference
Von Willebrand disease epidemiology, burden of illness and management: a systematic review
10.2147/jbm.s389241 · 2023 · External reference
Economic burden of major bleeding events in commercially insured patients with von Willebrand disease based on claims data from the United States
2021 · External reference
Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network
10.1111/hae.13473 · 2018 · External reference
Real-world healthcare costs and resource utilization in patients with von Willebrand disease and angiodysplasia
10.1080/14737167.2023.2211270 · 2023 · External reference
The impact of bleeding event frequency on health-related quality of life and work productivity outcomes in a European cohort of adults with haemophilia A: insights from the CHESS II study
10.1186/s13023-023-02690-w · 2023 · External reference
Long-term prophylaxis in von Willebrand disease
10.1097/01.mbc.0000167659.23262.18 · 2005 · External reference
ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease
10.1182/bloodadvances.2020003264 · 2021 · External reference
2025 ASH ISTH NBDF WFH monitoring report on the 2021 clinical guidelines on the diagnosis and management of von Willebrand disease
10.1182/bloodadvances.2025016512 · 2025 · External reference
Translating the success of prophylaxis in haemophilia to von Willebrand disease
10.1016/j.thromres.2020.12.030 · 2021 · External reference
Prophylaxis in severe forms of von Willebrand’s disease: results from the von Willebrand Disease Prophylaxis Network (VWD PN)
10.1111/j.1365-2516.2012.02916.x · 2013 · External reference
A phase III study comparing secondary long-term prophylaxis versus on-demand treatment with vWF/FVIII concentrates in severe inherited von Willebrand disease
2019 · External reference
von Willebrand factor/factor VIII concentrate (Wilate) prophylaxis in children and adults with von Willebrand disease
10.1182/bloodadvances.2023011742 · 2024 · External reference
Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results
10.1182/blood.2021014810 · 2022 · External reference
The von Willebrand disease prophylaxis network: exploring a treatment concept
10.1111/j.1538-7836.2006.02179.x · 2006 · External reference
Cost-effectiveness of long-term prophylaxis versus on-demand treatment with von Willebrand factor concentrate in severe inherited von Willebrand disease [abstract]
10.1182/blood-2020-136241 · 2020 · External reference
Diagnosis and treatment challenges in lower resource countries: state-of-the-art
10.1111/hae.14956 · 2024 · External reference
Cost-effectiveness of voncento prophylaxis vs on-demand treatment in von Willebrand disease in the United Kingdom
10.1182/bloodadvances.2024014376 · 2025 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Efficacy of regular prophylaxis with a plasma-derived von Willebrand factor/factor VIII concentrate with a 1:1 activity ratio in reducing heavy menstrual bleeding in girls/women with von Willebrand disease
10.1016/j.xagr.2025.100501 · 2025 · External reference
Efficacy of wilate prophylaxis in reducing nosebleeds in patients with severe VWD – a post-hoc analysis of the WIL-31 study
10.1177/10760296241306755 · 2024 · External reference
Efficacy and safety of plasma-derived von Willebrand factor/factor VIII concentrate (wilate) prophylaxis in children and adolescents with von Willebrand disease – WIL-31 study post hoc analysis
10.1016/j.rpth.2025.102719 · 2025 · External reference
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations
10.1016/j.hpopen.2021.100063 · 2022 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Utility valuation of health states for haemophilia and related complications in Europe and in the United States
10.1111/hae.13634 · 2019 · External reference
The cost-effectiveness of gene therapy for severe hemophilia B: a microsimulation study from the United States perspective
10.1182/blood.2021010864 · 2021 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Alternative valuations of work loss and productivity
10.1097/00043764-200101000-00005 · 2001 · External reference
A review of methods to measure health-related productivity loss
2007 · External reference
Unresolved reference
External reference
Measuring the effects of work loss on productivity with team production
10.1002/hec.1052 · 2006 · External reference
Unresolved reference
2023 · External reference
Unresolved reference
External reference
Changes in bleeding patterns in von Willebrand disease after institution of long-term replacement therapy: results from the von Willebrand Disease Prophylaxis Network
10.1097/mbc.0000000000000257 · 2015 · External reference
Unresolved reference
External reference
